RxDoctor Payments Data

Marie Cahill, NP

Adult Health · Corona, NYNPI 1073873717

Payments from drug & device makers

$1,140in general payments, 2019–2025

Across 44 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$356
  • AstraZeneca$190
  • Novo Nordisk$135
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$113
  • Lilly USA, LLC$82
  • GSK$63
  • plus $202 from 7 others

What the payments were for

  • Food & beverage$1,140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,140 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$26,405
Medicare patients
62
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$69,690
JanuviaSitagliptin Phosphate47$66,302
OzempicSemaglutide22$32,492
FarxigaDapagliflozin Propanediol30$31,231
XifaxanRifaximin12$18,390
EliquisApixaban15$9,657
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$8,318
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,404
Rosuvastatin Calcium118$1,919
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,859
Metoprolol Succinate106$1,747
Atorvastatin Calcium107$1,504
Losartan Potassium164$1,477
Albuterol Sulfate HfaAlbuterol Sulfate68$1,462
Amlodipine Besylate214$1,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$190$38,63542 claims
Novo NordiskOzempic$135$32,49222 claims
AbbVieSynthroid$54$96914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.

Other adult health in Corona

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →